GlassScriptPhysician profile
Marshall K Grossman
NPI 1770600116
$4,528.06
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,815 · 2020: $1,472 · 2021: $1,241.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.60 | 2019-2021 | |
| Amgen INC. | $586.09 | 2019-2021 | |
| Lilly USA, LLC | $555.33 | 2019-2021 | |
| Novo Nordisk INC | $327.74 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $302.48 | 2019-2021 | |
| Amarin Pharma, INC. | $270.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $256.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.14 | 2019-2021 | |
| Ibsa Pharma INC. | $185.97 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $146.41 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $125.93 | 2019-2021 | |
| Esperion Therapeutics, INC. | $113.96 | 2020-2021 | |
| Radius Health, INC. | $88.34 | 2020-2021 | |
| Insulet Corporation | $84.72 | 2019-2021 | |
| Acerus Pharmaceuticals Corporation | $76.63 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $66.93 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $55.35 | 2020 | |
| Horizon Therapeutics Plc | $53.11 | 2020-2021 | |
| Dexcom, INC. | $49.44 | 2019-2020 | |
| Abbott Laboratories | $48.60 | 2019-2020 | |
| Mannkind Corporation | $41.86 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.79 | 2021 | |
| Pfizer INC. | $38.10 | 2019 | |
| Antares Pharma, INC. | $26.56 | 2019 | |
| Becton, Dickinson and Company | $25.06 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.62 | 2021 | |
| Sun Pharmaceutical Industries INC. | $23.23 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.86 | 2020 | |
| Medtronic Minimed, INC. | $13.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Grossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.